NCT05155319View on ClinicalTrials.gov

Universal Influenza A Vaccine in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

October 10, 2023

Study Completion Date

October 10, 2023

Conditions
Human Influenza
Interventions
BIOLOGICAL

UFluA 20 µg each antigen/dose

Low dose

BIOLOGICAL

UFluA 60 µg each antigen/dose

High Dose

BIOLOGICAL

Placebo

Placebo

Trial Locations (2)

2100

Northern Beaches Clinical Research, Brookvale

6009

Linear Clinical Research, Nedlands

Sponsors
All Listed Sponsors
lead

Emergent BioSolutions

INDUSTRY